Stock listing

Xetra:RGN Repligen Corporation Aktie

German listing (Xetra) of Repligen Corporation · home listing NASDAQ:RGEN

Follow Repligen Corporation into a list and get an email when it puts out news.

Home listing price · NASDAQ:RGEN

$163.81 USD -8.86 (-5.1%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:RGEN

Past year +6.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$162.50 – $169.61 USDNov 20, 2026
Volume
697,683 sharesNov 20, 2026
Market cap
$10.47B USDAt the close on Nov 20, 2026 · price × 63.92M shares outstanding
52-week range
$100.99 – $198.87 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$208.5M USDMedian day 1.08M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Repligen Corporation logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:RGEN · Home$163.81 USD-8.86 (-5.1%)697,683$169.61$169.61$162.50$172.67Close on Nov 20, 2026
Frankfurt:RGN€154.35 EUR-1.65 (-1.1%)—€157.00€157.00€154.35€156.00Close on Nov 19, 2026
Munich:RGN€156.05 EUR-0.50 (-0.3%)—€156.05€156.05€156.05€156.55Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RGEN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$163.81-8.86-5.1%$169.61$169.61$162.50697,683
$172.67+10.49+6.5%$163.03$174.44$163.011,298,264
$162.18-0.60-0.4%$162.78$164.91$160.27770,857
$162.78-5.01-3.0%$166.14$166.79$162.48575,422
$167.79+1.27+0.8%$168.09$168.48$165.26510,106
$166.52-6.10-3.5%$167.71$169.40$164.17802,964
$172.62-1.36-0.8%$176.11$178.50$171.991,000,614
$173.98-4.96-2.8%$176.76$178.38$173.87678,643
$178.94+5.45+3.1%$174.29$181.02$172.391,096,247
$173.49+5.01+3.0%$169.35$175.00$168.051,069,907
$168.48-9.72-5.5%$175.60$176.66$168.031,332,421
$178.20-0.070.0%$183.40$188.50$174.391,058,127
$178.27+5.32+3.1%$175.54$181.55$173.001,019,566
$172.95-3.99-2.3%$178.12$178.12$172.541,576,318
$176.94-11.70-6.2%$175.37$180.31$171.234,472,060
$188.64+3.95+2.1%$188.42$191.05$185.28890,263
$184.69+8.89+5.1%$173.54$185.88$173.541,447,759
$175.80-4.37-2.4%$168.34$180.00$164.882,114,806
$180.17+3.24+1.8%$176.93$181.46$175.801,176,930
$176.93-1.78-1.0%$178.30$179.54$174.901,066,100
$178.71-1.30-0.7%$179.45$185.03$175.961,272,500
$180.01+1.13+0.6%$174.37$183.49$172.00903,900
$178.88+2.45+1.4%$176.50$180.67$174.37877,700
$176.43+1.01+0.6%$177.82$178.66$174.26769,100
$175.42-8.75-4.8%$183.81$186.00$172.391,213,300
$184.17+5.97+3.4%$178.28$185.99$177.491,043,100
$178.20+2.78+1.6%$175.42$181.07$175.391,216,900
$175.42+2.91+1.7%$172.51$177.96$169.731,259,300
$172.51-1.37-0.8%$171.73$173.82$169.90899,600
$173.88+10.04+6.1%$164.21$174.82$164.211,339,900
$163.84-3.38-2.0%$164.00$164.65$157.441,226,700
$167.22-7.64-4.4%$174.75$175.04$165.992,630,100
$174.86-14.64-7.7%$191.90$194.36$174.361,704,600
$189.50+7.80+4.3%$178.75$191.26$178.611,613,600
$181.70+4.47+2.5%$179.32$186.52$178.001,460,500
$177.23-15.00-7.8%$194.00$194.00$177.121,945,700
$192.23-2.34-1.2%$193.09$195.61$190.97730,400
$194.57+0.48+0.2%$196.00$196.65$190.981,139,000
$194.09+4.41+2.3%$187.25$198.87$187.111,567,100
$189.68-0.97-0.5%$189.92$191.51$186.911,502,400
$190.65+6.12+3.3%$184.10$192.49$183.751,602,600
$184.53-2.22-1.2%$186.38$188.95$181.71934,800
$186.75+6.04+3.3%$180.72$188.20$180.001,159,800
$180.71+3.82+2.2%$176.89$182.25$176.22857,600
$176.89-1.30-0.7%$179.10$179.10$176.291,359,700
$178.19+5.28+3.1%$174.93$178.65$173.241,087,100
$172.91-1.82-1.0%$174.90$178.55$171.66826,900
$174.73+6.73+4.0%$168.27$175.86$168.27891,300
$168.00+2.82+1.7%$166.74$168.42$162.10514,400
$165.18+0.50+0.3%$166.72$168.06$164.02944,600
$164.68-0.37-0.2%$162.68$165.04$161.14955,900
$165.05-3.48-2.1%$168.53$169.52$162.461,081,200
$168.53+0.93+0.6%$168.05$172.95$166.32779,400
$167.60-2.01-1.2%$167.26$169.51$165.00806,100
$169.61-3.33-1.9%$175.53$176.13$167.541,325,300
$172.94+2.92+1.7%$171.77$176.87$168.58959,300
$170.02-10.96-6.1%$180.70$182.57$167.421,405,100
$180.98+4.71+2.7%$174.17$181.07$174.01791,000
$176.27-5.76-3.2%$179.76$181.35$175.70818,500
$182.03+1.73+1.0%$179.90$183.09$179.14611,900
$180.30-1.39-0.8%$180.11$183.43$179.47539,100
$181.69+0.070.0%$181.62$185.34$178.981,142,346
$181.62+0.49+0.3%$180.60$183.05$176.281,497,952
$181.13+0.84+0.5%$179.66$182.43$175.751,096,900
$180.29+3.93+2.2%$174.61$188.73$173.141,591,700
Ticker
Xetra:RGN
Asset type
Stock
Exchange
Xetra
Currency
EUR

What changed lately

Latest news

All Repligen Corporation news

Repligen Corporation on 6ix

News releases
23 in the last 12 months · 130 in all · newest Nov 4, 2026 · oldest 2017
Calls
25 calls with a replay · 25 with a transcript · latest Oct 27, 2026
Decks
27 decks · latest Nov 18, 2026

Where Repligen Corporation is listed

ListingExchangeCountryCurrency
NASDAQ:RGEN · Home listingNASDAQUnited StatesUSD
gettex:RGNgettexGermanyEUR
Tradegate:RGNTradegateGermanyEUR
LS Exchange:870980LS ExchangeGermanyEUR
Lang & Schwarz:870980Lang & SchwarzGermanyEUR
B3:R2GE34B3BrazilBRL
Frankfurt:RGNFrankfurtGermanyEUR
Milan:1RGENMilanItalyEUR
BOATS:RGENBOATSUnited StatesUSD
BX Swiss:RGNBX SwissSwitzerlandCHF
Dusseldorf:RGNDusseldorfGermanyEUR
Munich:RGNMunichGermanyEUR
Stuttgart:RGNStuttgartGermanyEUR
Xetra:RGN · This pageXetraGermanyEUR

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$10.16B USD
P/E
Loss
EV/sales
12.6×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
5.0×
Gross margin
53.5%
Operating margin
2.3%
Net margin
−1.5%
Debt to equity
0.3×
Beta vs S&P 500
1.19

Forecasts

14 strong buy · 3 buy · 4 hold · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
203.21 USD · Analysts' mean
EPS, year to Dec 2026
2.07 · 20 analysts
Revenue, year to Dec 2026
848.8M · 20 analysts

Team and board

Officers

OfficerRole
Olivier LoeillotPreseident and Chief Executive Officer
Jason K. GarlandChief Financial Officer
James R. BylundChief Operating Officer
George ScottSenior Vice President, General Counsel
Jacob JohnsonVP, Investor Relations
Brian DouglassSenior Vice President and Chief Product Officer
Greg TitusSenior Vice President, Commercial Development
Jessica HamelineSenior Vice President, Business Development & Strategy
Keng Hock ChuaSenior Vice President, Commercial for Asia
Leslie GalvinVice President, Global Head, Human Resources
Neil WhitfieldSenior Vice President, Sales
Ralf KuriyelSenior Vice President, Research and Development
Heather EmsChief Information Officer
Violetta HughesChief Accounting Officer

Board

DirectorRole
Martin D. MadausChair of the Board
Carrie Eglinton MannerDirector
Glenn P. MuirDirector
Konstantin KonstantinovDirector
Maggie A. PaxDirector
Nicolas M. BarthelemyDirector
Rohin MhatreDirector

Events

Calls

CallWhenStatus
Repligen (NASDAQ:RGEN) Q3 2026 Earnings CallTue, Oct 27, 2026 · 8:00 AM ETReplay
Repligen (NASDAQ:RGEN) Q2 2026 Earnings CallTue, Jul 28, 2026 · 8:00 AM ETReplay
Repligen (NASDAQ:RGEN) Q1 2026 Earnings CallTue, May 05, 2026 · 8:00 AM ETReplay
Repligen (NASDAQ:RGEN) Q4 2025 Earnings CallTue, Feb 24, 2026 · 8:30 AM ETReplay
Repligen (NASDAQ:RGEN) Q3 2025 Earnings CallTue, Oct 28, 2025 · 8:30 AM ETReplay
Repligen (NASDAQ:RGEN) Q2 2025 Earnings CallTue, Jul 29, 2025 · 8:30 AM ETReplay
Repligen (NASDAQ:RGEN) Q1 2025 Earnings CallTue, Apr 29, 2025 · 8:30 AM ETReplay
Repligen (NASDAQ:RGEN) Q4 2024 Earnings CallThu, Feb 20, 2025 · 8:30 AM ETReplay
Repligen (NASDAQ:RGEN) Q3 2024 Earnings CallTue, Nov 12, 2024 · 8:30 AM ETReplay
Repligen (NASDAQ:RGEN) Q2 2024 Earnings CallTue, Jul 30, 2024 · 8:30 AM ETReplay
All 25 calls
CallWhenStatus
Repligen (NASDAQ:RGEN) Q1 2024 Earnings CallWed, May 01, 2024 · 8:30 AM ETReplay
Repligen (NASDAQ:RGEN) Q4 2023 Earnings CallWed, Feb 21, 2024 · 8:30 AM ETReplay
Repligen (NASDAQ:RGEN) Q3 2023 Earnings CallTue, Oct 31, 2023 · 8:30 AM ETReplay
Repligen (NASDAQ:RGEN) Q2 2023 Earnings CallWed, Aug 02, 2023 · 8:30 AM ETReplay
Repligen (NASDAQ:RGEN) Q1 2023 Earnings CallTue, May 02, 2023 · 8:30 AM ETReplay
Repligen (NASDAQ:RGEN) Q4 2022 Earnings CallWed, Feb 22, 2023 · 8:30 AM ETReplay
Repligen (NASDAQ:RGEN) Q3 2022 Earnings CallTue, Nov 01, 2022 · 8:30 AM ETReplay
Repligen (NASDAQ:RGEN) Q2 2022 Earnings CallTue, Aug 02, 2022 · 8:30 AM ETReplay
Repligen (NASDAQ:RGEN) Q1 2022 Earnings CallWed, Apr 27, 2022 · 8:30 AM ETReplay
Repligen (NASDAQ:RGEN) Q4 2021 Earnings CallThu, Feb 17, 2022 · 8:30 AM ETReplay
Repligen (NASDAQ:RGEN) Q3 2021 Earnings CallThu, Oct 28, 2021 · 8:30 AM ETReplay
Repligen (NASDAQ:RGEN) Q2 2021 Earnings CallTue, Jul 27, 2021 · 8:30 AM ETReplay
Repligen (NASDAQ:RGEN) Q1 2021 Earnings CallTue, May 04, 2021 · 8:30 AM ETReplay
Repligen (NASDAQ:RGEN) Q4 2020 Earnings CallWed, Feb 24, 2021 · 8:30 AM ETReplay
Repligen (NASDAQ:RGEN) Q3 2020 Earnings CallThu, Nov 05, 2020 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Oct 27, 2026 · Before open−2.4%
Q2 2026Jul 28, 2026 · Before open+10.9%
Q1 2026May 5, 2026 · Before open+6.3%
Q4 2025Feb 25, 2026−0.8%
Q3 2025Oct 28, 2025 · Before open−5.9%
Q2 2025Jul 29, 2025 · Before open+4.7%
Q1 2025Apr 29, 2025 · Before open−2.9%
Q4 2024Feb 19, 2025 · Before open+3.8%
Q3 2024Nov 12, 2024 · Before open+6.5%
Q2 2024Jul 30, 2024 · Before open+16.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 1, 2024 · Before open−3.6%
Q4 2023Feb 21, 2024 · Before open−2.8%
Q3 2023Oct 31, 2023 · Before open+17.9%
Q2 2023Aug 2, 2023 · Before open+2.0%
Q1 2023May 2, 2023 · Before open+2.4%
Q4 2022Feb 22, 2023 · Before open−4.5%
Q3 2022Nov 1, 2022 · Before open+1.7%
Q2 2022Aug 2, 2022 · Before open+11.7%
Q1 2022Apr 27, 2022 · Before open+10.5%
Q4 2021Feb 17, 2022 · Before open−0.9%

Open Events

Decks

DeckKindSlidesDate
Jefferies Global Healthcare Conference 2026Conference30 slidesNov 18, 2026
Wells Fargo 21st Annual Healthcare Conference 2026Conference32 slidesSeptember 2026
Q2 2026 Earnings PresentationEarnings29 slidesJul 28, 2026
Merger or Acquisition (July 2026)Merger or acquisition14 slidesJul 22, 2026
J.P. Morgan 2026 Healthcare ConferenceConference28 slidesJan 13, 2026
Investor Presentation (November 2025)Investor deck33 slidesNovember 2025
Bank of America Global Healthcare Conference 2025Conference28 slidesSep 25, 2025
Q1 2025 Earnings PresentationEarnings38 slidesApr 29, 2025
Merger or Acquisition (March 2025)Merger or acquisition11 slidesMar 4, 2025
J.P. Morgan 43rd Annual Healthcare Conference 2025Conference33 slidesJan 14, 2025
All 27 decks
DeckKindSlidesDate
Q1 2023 to Q2 2024 Earnings PresentationEarnings12 slidesNov 12, 2024
Investor Presentation (November 2024)Investor deck33 slidesNovember 2024
Earnings Presentation (September 2024)Earnings8 slidesSep 18, 2024
Corporate Update (September 2024)Corporate update9 slidesSep 18, 2024
42nd Annual J.P. Morgan Healthcare Conference (January 2024)Conference26 slidesJan 9, 2024
Merger or Acquisition (September 2023)Merger or acquisition9 slidesSep 26, 2023
Merger or Acquisition (April 2023)Merger or acquisition7 slidesApr 12, 2023
Investor Day (September 2022)Investor day73 slidesSep 20, 2022
Merger or Acquisition (December 2021)Merger or acquisition8 slidesDec 16, 2021
Merger or Acquisition (September 2021)Merger or acquisition8 slidesSep 16, 2021
Merger or Acquisition (June 2021)Merger or acquisition9 slidesJun 22, 2021
Merger or Acquisition (October 2020)Merger or acquisition9 slidesOct 27, 2020
Technical Presentation (December 2019)Technical18 slidesDecember 2019
Technical Presentation (June 2017)Technical24 slidesJun 19, 2017
Cytovance Biologics — Technical Presentation (March 2017)Technical14 slidesMar 14, 2017
Merger or Acquisition (June 2014)Merger or acquisition10 slidesJun 3, 2014
Merger or Acquisition (October 2011)Merger or acquisition5 slidesOct 28, 2011

Open Decks

Financings

RaiseDate
0.25% Convertible Senior Notes due 2031
Announced: about US$458.6M · J. Wood Capital Advisors LLC
Dealers: J. Wood Capital Advisors LLC (lead)
Use of proceeds: About $120.0 million to repurchase common stock from certain note purchasers; remainder for working capital and general corporate purposes, including possible acquisitions
Oct 30, 2026

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue738.3M634.4M632.4M801.5M670.5M366.3M270.2M194.0M141.2M104.5M
Cost of revenue352.0M359.8M353.9M345.8M279.3M156.6M119.1M86.5M67.0M47.1M
Gross profit386.2M274.6M278.4M455.7M391.3M209.6M151.1M107.5M74.2M57.4M
Research and development54.2M43.2M42.7M43.9M34.3M20.2M19.4M15.8M8.67M7.36M
Selling, general and administrative290.5M263.4M218.6M215.8M183.9M119.6M95.6M65.7M51.5M30.9M
Operating income55.2M-35.1M47.7M224.7M167.2M69.8M36.1M26.0M14.0M16.0M
Depreciation and amortization78.7M69.7M68.6M51.0M38.4M27.1M20.9M15.8M10.5M5.33M
EBITDA133.9M34.6M116.3M275.7M205.7M96.9M57.0M41.8M24.5M21.3M
Interest expense21.5M20.7M1.95M1.16M11.3M10.8M9.29M6.71M6.44M3.77M
Income before tax62.4M-27.0M56.7M219.1M153.5M59.2M26.2M21.4M7.25M11.7M
Income tax13.5M-1.52M21.1M33.2M25.3M-709.0K4.74M4.82M-21.1M11.0K
Net income48.9M-25.5M35.6M186.0M128.3M59.9M21.4M16.6M28.4M11.7M
Earnings per share, basic0.87-0.460.643.352.331.140.440.380.740.35
Earnings per share, diluted0.86-0.460.633.242.241.110.440.370.720.34

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents566.0M757.4M751.3M523.5M603.8M717.3M528.4M193.8M173.8M122.2M
Short-term investments201.6M000
Receivables158.6M134.1M124.2M116.2M117.4M71.4M43.1M33.0M27.6M15.2M
Inventory170.5M143.0M202.3M238.3M184.5M95.0M54.8M42.3M39.0M24.7M
Current assets1.14B1.07B1.11B998.1M931.7M902.4M641.8M275.7M242.8M184.2M
Property, plant and equipment186.6M197.7M207.4M190.7M125.0M66.9M48.5M32.2M22.4M15.0M
Goodwill1.11B1.03B987.1M855.5M860.4M618.3M468.4M326.7M327.3M59.5M
Total assets2.95B2.83B2.83B2.53B2.36B1.90B1.40B774.6M743.5M288.9M
Accounts payable30.0M32.1M19.6M27.6M36.2M16.9M11.4M10.5M7.28M5.06M
Current liabilities135.8M126.8M164.9M404.2M375.3M319.0M48.3M129.8M25.2M21.1M
Total debt542.2M525.6M
Total liabilities843.6M856.9M866.3M620.9M608.3M373.7M340.3M159.1M152.0M
Shareholders' equity2.11B1.97B1.96B1.91B1.75B1.53B1.06B615.6M591.5M168.8M
Shares outstanding56.3M56.1M55.8M55.6M55.3M54.8M52.1M43.9M43.6M33.8M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations117.4M175.4M113.9M172.1M119.0M62.6M67.2M32.8M17.5M7.52M
Capital spending-23.5M-25.7M-36.2M-84.8M-67.1M-22.5M-18.5M-10.6M-5.45M-4.33M
Free cash flow93.9M149.7M77.7M87.2M51.9M40.2M48.7M22.1M12.0M3.20M
Cash from investing-298.5M-86.4M-123.3M-233.2M-221.2M-201.4M-205.3M-14.0M-98.7M-49.2M
Cash from financing-15.2M-82.9M249.0M-13.3M961.0K305.9M484.9M3.41M129.9M112.1M
Share buybacks00-14.4M00
Change in cash-191.3M6.03M227.9M-80.4M-113.5M179.9M343.6M20.1M51.1M68.1M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 6, 2026Material contractSEC
10-Q · Quarterly reportOct 30, 2026Quarterly reportSEC
8-K · Current reportOct 30, 2026FinancingSEC
8-K · Current reportOct 27, 2026ResultsSEC
4 · Change in ownershipOct 8, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 7, 2026Big-stake noticeSEC
4 · Change in ownershipOct 6, 2026Insider tradeSEC
8-K · Current reportOct 6, 2026Acquisition or disposalSEC
144 · Notice of proposed saleOct 5, 2026Other filingsSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleOct 5, 2026Other filingsSEC
425Sep 30, 2026Other filingsSEC
4 · Change in ownershipSep 28, 2026Insider tradeSEC
4 · Change in ownershipSep 25, 2026Insider tradeSEC
144 · Notice of proposed saleSep 24, 2026Other filingsSEC
4 · Change in ownershipSep 22, 2026Insider tradeSEC
144 · Notice of proposed saleSep 21, 2026Other filingsSEC
8-K · Current reportSep 15, 2026Management or board changeSEC
425Sep 8, 2026Other filingsSEC
8-K · Current reportSep 8, 2026Current reportSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveSep 8, 2026Other filingsSEC
424B3 · ProspectusSep 4, 2026Offer documentSEC
144 · Notice of proposed saleSep 4, 2026Other filingsSEC
S-4/A · Registration statement, amendedSep 3, 2026Offer documentSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
S-4 · Registration statementAug 24, 2026Offer documentSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
144 · Notice of proposed saleAug 20, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
425Aug 3, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeJul 31, 2026Big-stake noticeSEC
10-Q · Quarterly reportJul 29, 2026Quarterly reportSEC
8-K · Current reportJul 28, 2026ResultsSEC
425Jul 23, 2026Other filingsSEC
425Jul 22, 2026Other filingsSEC
425Jul 22, 2026Other filingsSEC
8-K · Current reportJul 22, 2026ResultsSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
144 · Notice of proposed saleJul 16, 2026Other filingsSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
144 · Notice of proposed saleJun 25, 2026Other filingsSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
8-K · Current reportMay 15, 2026Meeting outcomeSEC
4 · Change in ownershipMay 8, 2026Insider tradeSEC
4 · Change in ownershipMay 8, 2026Insider tradeSEC
10-Q · Quarterly reportMay 6, 2026Quarterly reportSEC
8-K · Current reportMay 5, 2026ResultsSEC
DEFA14A · Additional proxy materialApr 27, 2026Meeting noticeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
144 · Notice of proposed saleApr 21, 2026Other filingsSEC
ARS · Annual report to shareholdersApr 2, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 2, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 2, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
8-K · Current reportFeb 24, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 5, 2026Big-stake noticeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 12, 2026Insider tradeSEC
8-K · Current reportJan 6, 2026Management or board changeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
144 · Notice of proposed saleNov 25, 2025Other filingsSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
144 · Notice of proposed saleNov 18, 2025Other filingsSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
144 · Notice of proposed saleNov 13, 2025Other filingsSEC
144 · Notice of proposed saleNov 12, 2025Other filingsSEC
10-Q · Quarterly reportNov 4, 2025Quarterly reportSEC
8-K · Current reportOct 28, 2025ResultsSEC
4 · Change in ownershipOct 6, 2025Insider tradeSEC
4 · Change in ownershipSep 26, 2025Insider tradeSEC
4 · Change in ownershipSep 11, 2025Insider tradeSEC
144 · Notice of proposed saleSep 10, 2025Other filingsSEC
UPLOAD · Letter from the SECSep 10, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedSep 8, 2025Big-stake noticeSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 4, 2025Insider tradeSEC
8-K · Current reportSep 2, 2025Management or board changeSEC
CORRESP · Letter to the SECAug 26, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 14, 2025Other filingsSEC
4 · Change in ownershipAug 12, 2025Insider tradeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportJul 29, 2025ResultsSEC
4 · Change in ownershipMay 21, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
8-K · Current reportMay 15, 2025Meeting outcomeSEC
144 · Notice of proposed saleMay 15, 2025Other filingsSEC
10-Q · Quarterly reportApr 29, 2025Quarterly reportSEC
8-K · Current reportApr 29, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 24, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 4, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 4, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 4, 2025Meeting noticeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipMar 20, 2025Insider tradeSEC
4 · Change in ownershipMar 19, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
PRE 14A · Preliminary proxy statementMar 17, 2025Meeting noticeSEC
144 · Notice of proposed saleMar 17, 2025Other filingsSEC
10-K · Annual reportMar 13, 2025Annual reportSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
NT 10-K · Late filing noticeMar 3, 2025Explanation requestSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
8-K · Current reportFeb 20, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2025Big-stake noticeSEC
4 · Change in ownershipDec 5, 2024Insider tradeSEC
4 · Change in ownershipNov 22, 2024Insider tradeSEC
144 · Notice of proposed saleNov 21, 2024Other filingsSEC
4 · Change in ownershipNov 21, 2024Insider tradeSEC
4 · Change in ownershipNov 21, 2024Insider tradeSEC
4 · Change in ownershipNov 20, 2024Insider tradeSEC
10-Q · Quarterly reportNov 18, 2024Quarterly reportSEC
10-Q/A · Quarterly report, amendedNov 18, 2024Quarterly reportSEC
10-Q/A · Quarterly report, amendedNov 18, 2024Quarterly reportSEC
10-K/A · Annual report, amendedNov 18, 2024Annual reportSEC
10-Q/A · Quarterly report, amendedNov 18, 2024Quarterly reportSEC
10-Q/A · Quarterly report, amendedNov 18, 2024Quarterly reportSEC
10-Q/A · Quarterly report, amendedNov 18, 2024Quarterly reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
NT 10-Q · Late filing noticeNov 12, 2024Explanation requestSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
8-K · Current reportNov 12, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedOct 23, 2024Big-stake noticeSEC
8-K · Current reportSep 18, 2024ResultsSEC
4 · Change in ownershipSep 12, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedSep 10, 2024Big-stake noticeSEC
144 · Notice of proposed saleSep 10, 2024Other filingsSEC
4 · Change in ownershipSep 4, 2024Insider tradeSEC
4 · Change in ownershipSep 4, 2024Insider tradeSEC
4/A · Change in ownership, amendedAug 19, 2024Insider tradeSEC
UPLOAD · Letter from the SECAug 12, 2024Other filingsSEC
CORRESP · Letter to the SECAug 6, 2024Other filingsSEC
4 · Change in ownershipAug 5, 2024Insider tradeSEC
144 · Notice of proposed saleAug 2, 2024Other filingsSEC
4 · Change in ownershipAug 1, 2024Insider tradeSEC
4 · Change in ownershipAug 1, 2024Insider tradeSEC
144 · Notice of proposed saleAug 1, 2024Other filingsSEC
144 · Notice of proposed saleAug 1, 2024Other filingsSEC
10-Q · Quarterly reportJul 30, 2024Quarterly reportSEC
8-K · Current reportJul 30, 2024ResultsSEC
UPLOAD · Letter from the SECJul 24, 2024Other filingsSEC
8-K · Current reportJul 15, 2024Current reportSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
8-K · Current reportJun 14, 2024Management or board changeSEC
8-K · Current reportJun 13, 2024Current reportSEC
4 · Change in ownershipMay 22, 2024Insider tradeSEC
144 · Notice of proposed saleMay 21, 2024Other filingsSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC

This page holds 200 of 1,004 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Repligen Corporation’s releases · as of Oct 30, 2026

Common shares
63,923,738
Fully diluted
63,923,738

Fully diluted

LineSharesAs of
Common shares63,923,738Oct 23, 2026

Share count over time

CountShares
Oct 23, 202663,923,738

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Fidelity7.35MUS$1.41BSep 30, 2026
BlackRock5.73MUS$1.1BSep 30, 2026
Vanguard5.17MUS$993MSep 30, 2026
T. Rowe Price3.43MUS$659MSep 30, 2026
United Capital Financial Advisors, LLC2.79MUS$536MSep 30, 2026
Invesco2.13MUS$410MSep 30, 2026
Sun Life2.03MUS$392MSep 30, 2026
State Street1.85MUS$356MSep 30, 2026
Ameriprise1.69MUS$325MSep 30, 2026
Maverick Capital LTD1.42MUS$272MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Rtw Investments, LP1.39MUS$266MSep 30, 2026
William Blair Investment Management, LLC1.24MUS$239MSep 30, 2026
UBS1.17MUS$224MSep 30, 2026
BNY1.09MUS$209MSep 30, 2026
Geode Capital1.09MUS$209MSep 30, 2026
Congress Asset Management Co1.02MUS$196MSep 30, 2026
Stephens Investment Management Group LLC955KUS$183MSep 30, 2026
Dimensional938KUS$180MSep 30, 2026
Franklin Templeton923KUS$164MSep 30, 2026
Wasatch Advisors LP907KUS$174MSep 30, 2026
AllianceBernstein796KUS$153MSep 30, 2026
Goldman Sachs748KUS$144MSep 30, 2026
Bamco Inc741KUS$142MSep 30, 2026
Fred Alger Management, LLC735KUS$141MSep 30, 2026
Capital Group718KUS$138MSep 30, 2026
Morgan Stanley703KUS$135MSep 30, 2026
Conestoga Capital Advisors, LLC701KUS$135MSep 30, 2026
Holocene Advisors, LP681KUS$131MSep 30, 2026
First Trust636KUS$122MSep 30, 2026
Schroders630KUS$121MSep 30, 2026
Voya Investment Management LLC602KUS$116MSep 30, 2026
Geneva Capital Management LLC592KUS$114MSep 30, 2026
BNP Paribas559KUS$107MSep 30, 2026
Viking Global Investors LP531KUS$102MSep 30, 2026
Schwab482KUS$92.6MSep 30, 2026
Northern Trust455KUS$87.5MSep 30, 2026
Thrivent Financial for Lutherans432KUS$83.1MSep 30, 2026
Janus Henderson405KUS$77.9MSep 30, 2026
Bank of America400KUS$76.9MSep 30, 2026
TimesSquare Capital Management, LLC397KUS$76.4MSep 30, 2026
Sei Investments Co378KUS$72.7MSep 30, 2026
Artemis Investment Management LLP374KUS$72MSep 30, 2026
Barclays356KUS$68.5MSep 30, 2026
Los Angeles Capital Management LLC342KUS$65.8MSep 30, 2026
Primecap Management Co325KUS$62.5MSep 30, 2026
Impax Asset Management Group plc296KUS$56.9MSep 30, 2026
American Capital Management Inc280KUS$53.9MSep 30, 2026
Granahan Investment Management, LLC277KUS$53.2MSep 30, 2026
Perceptive Advisors LLC272KUS$52.4MSep 30, 2026
Df Dent & Co Inc265KUS$50.9MSep 30, 2026

This page holds 50 of 511 holders. Open Shareholders

Funds

HolderSharesValueAs of
iShares Core S&P Mid-Cap ETF1.81MUS$248MJun 30, 2026
Vanguard Total Stock Market Index Fund1.7MUS$232MJun 30, 2026
Vanguard Small-Cap Index Fund1.23MUS$168MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.963KUS$131MJun 30, 2026
MFS Mid Cap Growth Fund862KUS$107MMay 31, 2026
Vanguard Small-Cap Growth Index Fund709KUS$96.7MJun 30, 2026
Wasatch Core Growth Fund674KUS$92MJun 30, 2026
First Trust NYSE Arca Biotechnology Index Fund632KUS$86.2MJun 30, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.619KUS$84.5MJun 30, 2026
Vanguard Extended Market Index Fund609KUS$83MJun 30, 2026
Show 50 holders
HolderSharesValueAs of
Select Medical Technology and Devices Portfolio520KUS$64.5MMay 31, 2026
Columbia Small Cap Growth Fund509KUS$63.1MMay 31, 2026
Select Health Care Portfolio460KUS$57MMay 31, 2026
Conestoga Small Cap Fund432KUS$58.9MJun 30, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund429KUS$53.1MMay 31, 2026
Vanguard Explorer Fund394KUS$55.6MJul 31, 2026
Congress Small Cap Growth Fund385KUS$54.3MJul 31, 2026
iShares Biotechnology ETF378KUS$51.6MJun 30, 2026
T. Rowe Price Institutional Small-Cap Stock Fund338KUS$46.1MJun 30, 2026
VIP Mid Cap Portfolio323KUS$44.1MJun 30, 2026
Invesco Discovery Fund305KUS$37.8MMay 31, 2026
Fidelity Mid-Cap Stock Fund300KUS$42.3MJul 31, 2026
Baron Discovery Fund274KUS$37.3MJun 30, 2026
Fidelity Extended Market Index Fund272KUS$33.8MMay 31, 2026
Fidelity Advisor Health Care Fund270KUS$38.1MJul 31, 2026
State Street(R) SPDR(R) Portfolio S&P 400(TM) Mid Cap ETF268KUS$36.6MJun 30, 2026
Voya Small Cap Growth Fund257KUS$31.9MMay 31, 2026
Franklin Small-Mid Cap Growth Fund257KUS$36.2MJul 31, 2026
Vanguard Capital Opportunity Fund248KUS$33.8MJun 30, 2026
Franklin Small Cap Growth Fund246KUS$34.7MJul 31, 2026
Baron Asset Fund230KUS$31.4MJun 30, 2026
Thrivent Small Cap Stock Fund222KUS$31.3MJul 31, 2026
U.S. Small Cap Portfolio220KUS$31MJul 31, 2026
BNY Mellon Small/Mid Cap Growth Fund219KUS$29.9MJun 30, 2026
iShares Russell Mid-Cap ETF219KUS$29.8MJun 30, 2026
Alger Small Cap Focus Fund212KUS$29.9MJul 31, 2026
Columbia Acorn Fund212KUS$28.9MJun 30, 2026
Fidelity Mid Cap Index Fund202KUS$28.4MJul 31, 2026
AB Small Cap Growth Portfolio195KUS$26.6MJun 30, 2026
Bridge Builder Small/Mid Cap Growth Fund187KUS$25.6MJun 30, 2026
Invesco Main Street Small Cap Fund184KUS$25.1MJun 30, 2026
Janus Henderson Triton Fund178KUS$24.3MJun 30, 2026
AB Discovery Growth Fund, Inc.177KUS$24.1MJun 30, 2026
Fidelity U.S. Equity Central Fund176KUS$24MJun 30, 2026
Dimensional U.S. Small Cap ETF176KUS$24.8MJul 31, 2026
iShares S&P Mid-Cap 400 Growth ETF174KUS$23.7MJun 30, 2026
Vanguard Health Care Index Fund161KUS$19.9MMay 31, 2026
Columbia Select Mid Cap Growth Fund149KUS$18.4MMay 31, 2026
Invesco Main Street Mid Cap Fund145KUS$19.8MJun 30, 2026
Schwab U.S. Mid-Cap ETF143KUS$17.7MMay 31, 2026

This page holds 50 of 507 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Loeillot Olivier
Director, Officer: Chief Executive Officer
Sale1,333USD 178.75US$238KOct 5, 2026
Loeillot Olivier
Director, Officer: Chief Executive Officer
Sale4,202USD 190.00US$798KOct 5, 2026
Loeillot Olivier
Director, Officer: Chief Executive Officer
Sale8,404USD 190.00US$1.6MSep 24, 2026
Loeillot Olivier
Director, Officer: Chief Executive Officer
Sale4,542USD 190.00US$863KSep 24, 2026
Loeillot Olivier
Director, Officer: Chief Executive Officer
Sale5,426USD 180.00US$977KSep 21, 2026
Loeillot Olivier
Director, Officer: Chief Executive Officer
Sale3,035USD 165.90US$504KSep 4, 2026
Loeillot Olivier
Director, Officer: Chief Executive Officer
Sale5,426USD 180.00US$977KAug 20, 2026
Garland Jason K
Officer: CFO
Sale530USD 150.00US$79,500Jul 16, 2026
Garland Jason K
Officer: CFO
Sale733USD 145.00US$106KJun 25, 2026
Loeillot Olivier
Director, Officer: Chief Executive Officer
Sale3,832USD 140.00US$536KApr 21, 2026

Big stakes

StakeStakeSharesDateFiling
FMR LLC13.00%7.36MSep 30, 2026Schedule 13G
BlackRock, Inc.9.30%5.2MMar 31, 2025Schedule 13G
Vanguard Capital Management LLC5.00%2.83MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Glenn P. Muir
Other companies: Cytek Biosciences, Inc. (Director · Since at least Jun 10, 2026); Neuronetics, Inc. (Board Member · Since at least Jun 27, 2018); G1 Therapeutics Inc (Director · May 16, 2017 – Sep 18, 2024 · Past); Lifeward Ltd. (Director · Dec 31, 2015 – Jun 27, 2017 · Past); Hologic Inc (Executive VP and CFO · Feb 1, 2006 – May 8, 2014 · Past)
Director · Since at least Sep 14, 2015
Paul Schimmel
Other companies: aTyr Pharma, Inc. (Director · Since at least May 6, 2015); Alnylam Pharmaceuticals, Inc. (Co-founder and member of the Board of Directors · Since at least Jan 31, 2006); Tocagen Inc (Director · Apr 12, 2017 – Oct 4, 2019 · Past); Sirtris Pharmaceuticals Inc (Director · May 22, 2007 – Nov 30, 2007 · Past); Alkermes plc (Director · Mar 2, 2006 – Jun 15, 2007 · Past)
Director · Aug 11, 2006 – Jun 14, 2007 · Past
John Cox
Other companies: Dyne Therapeutics, Inc. (President and Chief Executive Officer · Since at least Mar 25, 2024); Sigilon Therapeutics Inc (Director · Dec 3, 2020 – Aug 11, 2023 · Past); Bioverativ Inc (Chief Executive Officer, Director · Dec 22, 2016 – Mar 8, 2018 · Past); Biogen Inc. (EVP Pharmaceutical Oper & Tech · Nov 1, 2011 – Apr 1, 2016 · Past)
Director · Nov 15, 2013 – Mar 24, 2020 · Past
Nicolas M. Barthelemy
Other companies: 908 Devices Inc. (Director · Dec 17, 2020 – Jun 15, 2022 · Past); Twist Bioscience Corporation (Director · Oct 24, 2019 – Nov 21, 2022 · Past); Standard BioTools Inc. (Director · Mar 23, 2017 – Apr 1, 2022 · Past)
Director · Since at least May 11, 2016
Martin Madaus
Other companies: Azenta, Inc. (interim President and CEO · Since Aug 24, 2026); Haemonetics Corporation (Director · Since at least Jul 24, 2026)
Chair of the Board · Since at least Jan 6, 2026
Tony Hunt
Other companies: BioLife Solutions, Inc. (Director · Since at least Dec 20, 2024); 908 Devices Inc. (Director · Since at least Mar 2, 2022)
Director · Since at least Nov 19, 2020
Glenn L Md Cooper
Other companies: Fortress Biotech, Inc. (See Remarks, Director · Sep 13, 2011 – Nov 30, 2012 · Past)
Director · Sep 16, 2010 – May 23, 2019 · Past
Manner Carrie Eglinton
Other companies: OraSure Technologies, Inc. (President & CEO, Director · Since at least Jun 4, 2025)
Director · Since at least May 15, 2025
Margaret Pax
Other companies: Alimera Sciences Inc (Director · Nov 7, 2023 – Sep 16, 2024 · Past)
Director · Since at least Mar 18, 2024
Rohin Mhatre
Other companies: Parabilis Medicines, Inc. (Chief Technical Operations Officer · Since at least Jun 9, 2026)
Director · Since at least Mar 1, 2020
All 36 people
PersonSeat
Violetta Hughes
Other companies: Azenta, Inc. (VP, Chief Accounting Officer · Aug 31, 2023 – Feb 3, 2025 · Past)
Chief Accounting Officer · Since at least Sep 1, 2025
Alexander RichDirector · Dec 15, 2011 – Dec 15, 2011 · Past
Alfred Lewis GoldbergDirector · Jul 1, 2008 – May 21, 2015 · Past
Brian DouglassSenior Vice President and Chief Product Officer · Since at least May 7, 2026
Carrie Eglinton MannerDirector · Since at least Nov 5, 2026
Christine GebskiSee Remarks · Feb 25, 2021 – May 14, 2024 · Past
Earl Webb HenryDirector · Dec 12, 2007 – May 9, 2013 · Past
George ScottSenior Vice President, General Counsel · Since at least Nov 4, 2026
Greg TitusSenior Vice President, Commercial Development · Since at least Nov 4, 2026
Hal LandyVice President · Jun 19, 2007 – Jun 19, 2007 · Past
Heather EmsChief Information Officer · Since at least Nov 4, 2026
Jacob JohnsonVP, Investor Relations · Since at least Apr 8, 2025
James R. BylundChief Operating Officer · Since at least Feb 25, 2021
Jason K. GarlandChief Financial Officer · Since at least Jun 25, 2026
Jessica HamelineSenior Vice President, Business Development & Strategy · Since at least Nov 4, 2026
Jon SnodgresChief Financial Officer · Jul 14, 2015 – May 16, 2023 · Past
Karen A DawesDirector · Since at least Feb 27, 2024
Keng Hock ChuaSenior Vice President, Commercial for Asia · Since at least Nov 4, 2026
Konstantin KonstantinovDirector · Since at least May 18, 2026
Leslie GalvinVice President, Global Head, Human Resources · Since at least Nov 4, 2026
Maggie A. PaxDirector · Since at least May 18, 2026
Michael HallChief Medical Officer · Mar 12, 2012 – Mar 12, 2012 · Past
Neil WhitfieldSenior Vice President, Sales · Since at least Nov 4, 2026
Olivier LoeillotPreseident and Chief Executive Officer · Since at least Oct 2, 2023
Ralf KuriyelSenior Vice President, Research and Development · Since at least Feb 28, 2018
Thomas F Ryan JrDirector · Dec 9, 2005 – Mar 1, 2022 · Past

Open People

Log in to ask 6ix AI your own questions about Repligen Corporation.